Earnings History Data for Infinity Pharmaceuticals, Inc. (INFI) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
28-03-2023	AH	After the close (Mar 28)	INFI	Infinity Pharmaceuticals	18.00	-0.11	-0.12	0.00	Infinity Pharmaceuticals GAAP EPS of -$0.50 misses by $0.11, revenue of $2.59M misses by $11.31M [3/28/2023 4:48 PM]	0.1962	0.0 (1.92%)	0.19	0.0 (-1.30%)	0.17 - 1.76	343,417	870,000	7,044
Infinity Pharmaceuticals GAAP EPS of -$0.50 misses by $0.11, revenue of $2.59M misses by $11.31M [3/28/2023 4:48 PM]
14-11-2022	PM	7:30 AM ET (Nov 14)	INFI	Infinity Pharmaceuticals, Inc.	101.78	-0.12	-0.05	-0.12	Infinity Pharmaceuticals GAAP EPS of -$0.12, revenue of $0.71M [11/14/2022 7:09 AM]	0.7468	-0.44 (-37.24%)	1.11	-0.08 (-6.72%)	0.46 - 2.81	3,003,527	360,000	11,707
Infinity Pharma falls 24% on Q3 revenue miss [11/14/2022 1:31 PM] Infinity Pharmaceuticals GAAP EPS of -$0.12, revenue of $0.71M [11/14/2022 7:09 AM] Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib [Nov-14-22 07:05AM]
09-08-2022	AH	4:05 PM ET (Aug 9)	INFI	Infinity Pharmaceuticals, Inc.	64.15	-0.13	-0.14	-0.13	Infinity Pharmaceuticals GAAP EPS of -$0.13, revenue of $0.69M [8/9/2022 4:02 PM]	1.02	0.28 (37.84%)	0.90	0.17 (22.30%)	0.46 - 3.89	2,918,313	310,000	158,082
Infinity Pharmaceuticals GAAP EPS of -$0.13, revenue of $0.69M [8/9/2022 4:02 PM] Infinity Pharma stock gains ~24% on survival analysis data for a phase 2 trial, Q2 results [8/10/2022 12:17 PM]
03-05-2022	AH	4:05 PM ET (May 3)	INFI	Infinity Pharmaceuticals	71.00	-0.14	-0.14	0.00	Infinity Pharmaceuticals GAAP EPS of -$0.14 in-line, revenue of $0.65M beats by $0.39M [5/3/2022 4:14 PM]	0.8125	-0.03 (-3.27%)	0.88	0.04 (4.76%)	0.74 - 3.89	1,064,038	610,000	2,150
Infinity Pharmaceuticals GAAP EPS of -$0.14 in-line, revenue of $0.65M beats by $0.39M [5/3/2022 4:14 PM] Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results [May-03-22 04:05PM] Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates [May-03-22 05:45PM]
29-03-2022	AH	4:05 PM ET (Mar 29)	INFI	Infinity Pharmaceuticals, Inc.	88.15	-0.13	-0.14	-0.17	Infinity Pharmaceuticals GAAP EPS of -$0.53 in-line, revenue of $1.86M beats by $0.16M [3/29/2022 4:12 PM]	1.15	0.15 (15.54%)	0.99	-0.01 (-0.53%)	0.82 - 3.89	3,058,749	620,000	15,412
Infinity Pharmaceuticals GAAP EPS of -$0.53 in-line, revenue of $1.86M beats by $0.16M [3/29/2022 4:12 PM] Infinity Pharmaceuticals stock soars 25% after FY21 revenue beat [3/30/2022 12:38 PM] Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights [Mar-29-22 04:05PM] Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates [Mar-29-22 08:15PM]
02-11-2021	AH	4:05 PM ET (Nov 2)	INFI	Infinity Pharmaceuticals, Inc.	228.90	-0.12	-0.14	-0.16	Infinity Pharmaceuticals EPS beats by $0.01, misses on revenue [11/2/2021 4:22 PM]	2.69	0.07 (2.47%)	2.63	0.0 (0.00%)	1.06 - 5.98	1,725,531	1,100,000	3,286
Infinity Pharmaceuticals EPS beats by $0.01, misses on revenue [11/2/2021 4:22 PM] Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update [Nov-02-21 04:05PM] Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Misses Revenue Estimates [Nov-02-21 06:15PM]
27-07-2021	PM		INFI	Infinity Pharmaceuticals, Inc.	204.00	-0.13	-0.13	0.00	Infinity Pharmaceuticals EPS beats by $0.01, beats revenue; issues guidance [7/27/2021 7:39 AM]	1.51	-0.70 (-31.76%)	1.65	-0.57 (-25.68%)	0.82 - 5.98	11,529,345	2,340,000	2,215,488
Infinity Pharmaceuticals EPS beats by $0.01, beats revenue; issues guidance [7/27/2021 7:39 AM] Infinity Pharma updates data from bladder and breast cancer trials [7/27/2021 8:22 AM] Oragenics, EyeGate Pharmaceuticals leads healthcare gainers; Infinity Pharmaceuticals, NanoVibronix among major losers [7/27/2021 11:00 AM] Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC) [Jul-27-21 07:31AM] Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update [Jul-27-21 07:30AM] Infinity Pharma Reports Positive Results for Cancer Drug Eganelisib and Earnings [Jul-27-21 05:25AM] Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates [Jul-27-21 08:45AM] Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings [Jul-27-21 10:40AM]
13-05-2021	AH	4:05 PM ET (May 13)	INFI	Infinity Pharmaceuticals, Inc.	257.96	-0.15	-0.14	-0.19	Infinity Pharmaceuticals EPS misses by $0.01, beats on revenue [5/13/2021 4:14 PM]	2.72	0.07 (2.44%)	2.85	0.19 (7.14%)	0.78 - 5.98	1,405,517	1,700,000	36,654
Infinity Pharmaceuticals EPS misses by $0.01, beats on revenue [5/13/2021 4:14 PM] Infinity Pharmaceuticals, Inc. to Host Earnings Call [May-13-21 02:30PM] Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates [May-13-21 06:35PM] Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update [May-13-21 04:05PM]
16-03-2021	AH	4:05 PM ET (Mar 16)	INFI	Infinity Pharmaceuticals, Inc.	275.71	-0.17	-0.16	-0.20	Infinity Pharmaceuticals EPS misses by $0.01, beats on revenue [3/16/2021 4:10 PM]	3.23	0.13 (4.19%)	2.86	-0.24 (-7.74%)	0.60 - 5.98	2,351,712	2,306,758	31,463
Infinity Pharmaceuticals EPS misses by $0.01, beats on revenue [3/16/2021 4:10 PM] Infinity posts FY results, 2021 forecast [3/16/2021 4:24 PM] Infinity Pharmaceuticals, Inc. to Host Earnings Call [Mar-16-21 02:30PM] Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development [Mar-16-21 04:05PM] Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates [Mar-16-21 05:35PM] Infinity Pharmaceuticals: Q4 Earnings Insights [Mar-16-21 04:35PM]
09-11-2020	AH	4:05 PM ET (Nov 9)	INFI	Infinity Pharmaceuticals, Inc.	64.76	-0.16	-0.15	-0.20	Infinity Pharmaceuticals EPS misses by $0.01, beats on revenue [11/9/2020 4:23 PM]	1.25	0.10 (9.13%)	1.15	0.0 (0.00%)	0.60 - 1.68	781,096	241,980	7,100

30-07-2020	AH	4:05 PM ET (Jul 30)	INFI	Infinity Pharmaceuticals, Inc.	47.67	-0.16	-0.20	-0.18	Infinity Pharmaceuticals EPS beats by $0.04, beats on revenue [7/30/2020 4:14 PM]	0.8961	0.07 (8.20%)	0.89	0.06 (7.46%)	0.60 - 1.68	749,364	299,926	36,591